Eterna Therapeutics Inc erna Stock Soars Following Appointment of Megan Yung As Chief Strategy Officer

Eterna Therapeutics Inc. (ERNA) Stock Soars Following Appointment of Megan Yung as Chief Strategy Officer

Eterna Therapeutics Inc. (NASDAQ: ERNA) has recently named Megan Yung as their new Chief Strategy Officer and General Counsel. This appointment has led to a significant boost in the company’s stock, with shares rising by an impressive 21.49% on May 26th.

In her new role, Ms. Yung will collaborate closely with Eterna’s senior leadership and the Board of Directors to formulate and advance the company’s corporate strategy. In addition, she will be responsible for overseeing all legal activities, including licensing and intellectual property matters.

Ms. Yung brings a wealth of experience to Eterna. She holds a J.D. from The George Washington University Law School and most recently served as Deputy General Counsel and Vice President, Head of Intellectual Property at SQZ Biotechnologies. In her previous position, she played a crucial role in managing intellectual property, regulatory compliance, public company reporting, business development activities, and negotiations, as well as government affairs.

Before her tenure at SQZ, Ms. Yung held in-house counsel positions where she was a key member of deal teams involved in critical financing deals, such as venture capital and private equity financing. She also served as the chief counsel for all litigation matters, including intellectual property, employment issues, and class action lawsuits. Ms. Yung’s extensive experience was honed during her time as an intellectual property attorney at renowned firms such as Quinn Emanuel Urquhart & Sullivan, Mintz Levin Cohn Ferris Glovsky and Popeo, and Foley & Lardner. Throughout her career, she represented and provided guidance to biotech and pharmaceutical companies in patent litigation, prosecution, and intellectual property strategy.